Big news for NF! NFlection Therapeutics announced today positive results from its Phase 2b clinical trial evaluating NFX‑179 Gel as a treatment for cutaneous neurofibromas (cNFs) in people with neurofibromatosis type 1 (NF1). The topical gel significantly reduced the size of cNFs across multiple efficacy endpoints and was generally well tolerated. Based on the favorable efficacy and tolerability profile NFX‑179 Gel demonstrated in the study, NFlection plans to meet with U.S. and European regulators and move the program to Phase 3 development in 2024. The Children’s Tumor Foundation is a proud impact investor in this study. CTF President Annette Bakker said of this terrific news: “In addition to developing efficient preclinical and clinical NF test platforms, CTF is dedicated to investing in new medicines for people with NF. Our support for NFlection demonstrates that commitment. People with NF1 with cutaneous neurofibromas have been overlooked for a long time and are desperate for safe and easy-to-apply treatment options.”
Read the NFlection press release here.
Read more about CTF’s impact investment in NFlection here.
